



Common causes of visual impairment in the elderly

Mashaeh Al-Namaeh¹

¹ Eye Research Center, Wayne, PA, USA

ABSTRACT

Background: Aging is not a disease; rather, it is a process. As people age, visual impairment (VI) becomes more common. In 2010, the overall prevalence rate of vision impairment in all races was 25.66% in individuals aged ≥ 80 years, according to the estimate of the National Eye Institute at the National Institutes of Health. This review aimed to address the common causes of VI in the elderly.

Methods: In this narrative review, an electronic search of the PubMed/MEDLINE database was conducted using “visual impairment” and “elderly” for the period between January 2010 and April 2021, to include randomized clinical trials and observational studies concerning VI in the elderly. The selected time period was chosen to provide an updated review.

Results: The search yielded 2,955 articles published over the period of more than 11 years. The relevant randomized clinical trials or observational studies were included and reviewed. Cataracts, refractive errors, open-angle glaucoma, age-related macular degeneration, and diabetic retinopathy were the most common age-related ocular disorders leading to VI if untreated in the elderly. The loss of visual acuity can adversely affect quality of life in the elderly. Difficulty with activities of daily living related to VI can lead to social isolation, depression, and anxiety. Loss of vision in the elderly is linked to an increased risk of falls, hip fracture, depression, and poor quality of life.

Conclusions: The most common causes of VI in the elderly are cataracts and refractive errors. VI in most ocular diseases is more prevalent in women than in men due to longer lifespan. The overall prevalence of the main causes of VI in the elderly is expected to increase; therefore, health policymakers should consider this when planning for the health-enhancement program of the population.

KEY WORDS

visual impairment, elderly, cataracts, refractive error, age-related macular degeneration, glaucoma, diabetic retinopathy, policymaker, health-enhancement program

INTRODUCTION

Aging is a process that is not considered as a disease. Individuals aged 65 or more years are considered elderly [1]. Presbyopia, reduced contrast sensitivity, reduced dark/light adaptation, and glare delay recovery are common visual changes that are considered part of normal aging physiology. However, with age, visual impairment (VI) becomes more common [1-5]. VI is classified according to visual acuity of the best-seeing eye into mild ($< 20/30$ to $\geq 20/60$), moderate ($< 20/60$ to $\geq 20/200$), and severe ($< 20/200$ to $\geq 20/400$). Blindness is defined as a visual acuity of $< 20/400$ in the best-seeing eye [6].

Correspondence: Mashaeh Al-Namaeh, Eye Research Center, Wayne, PA 19087, USA. Email: alnamaeh@eyeresearchcenter.org. ORCID iD: <https://orcid.org/0000-0002-5253-1175>

How to cite this article: Al-Namaeh M. Common causes of visual impairment in the elderly. *Med Hypothesis Discov Innov Ophthalmol*. 2021 Winter; 10(4): 191-200. <https://doi.org/10.51329/mehdiophthal1438>

Received: 25 July 2021; Accepted: 24 October 2021



Copyright © Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.



In 2010, among individuals aged ≥ 80 years, the overall prevalence rates of VI in all races, white Americans, Hispanics, and African Americans (AAs) were 25.66%, 27.17%, 19.11%, and 16.68%, respectively [7]. Additionally, in individuals aged ≥ 80 years, the overall blindness rates among AAs, white Americans, other races, and Hispanics were 9.21%, 8.41%, 6.32%, 3.46%, and 2.15%, respectively [7]. In a systematic review and meta-analysis, the global number of blind individuals in 2020 was estimated at 43.3 million, of whom 23.9 million were female; the number with moderate and severe VI was estimated at 295 million, of whom 163 million were female; and the number with mild VI was estimated at 258 million, of whom 142 million were female. By 2050, the global numbers of individuals with blindness, moderate and severe VI, mild VI, and uncorrected presbyopia are predicted to reach 61.0 million, 474 million, 360 million, and 866 million, respectively [8]. The prevalence of VI differs based on the place of study; for example, the prevalence in individuals aged ≥ 80 years in Yugan County, China, was reported as 56.6% [9].

This review aimed to address common causes of VI in the elderly, including cataracts, refractive errors, open-angle glaucoma, age-related macular degeneration (ARMD), and diabetic retinopathy (DR).

METHODS

In this narrative review, an electronic search of the PubMed/MEDLINE database was conducted using the keywords “visual impairment” and “elderly”, including relevant randomized clinical trials and observational studies published between January 2010 and April 2021. The search syntax (“visual impairment” AND elderly) was used to provide an updated comprehensive review with inclusion of the most relevant articles.

RESULTS

The search yielded 2,955 articles published over the period of more than 11 years. The relevant randomized clinical trials or observational studies were included and reviewed. Cataracts [6, 9-18], refractive error [6, 10, 14, 16, 18], glaucoma [13], ARMD [6, 12, 13, 17], DR [13], and myopic degeneration [12, 14, 16] were the main causes of age-related ocular disorders in the elderly. Articles concerning the main causes of VI in the elderly are reviewed in the Discussion section below. Table 1 summarizes the most common causes of ocular disorders in the elderly outlined in some included studies.

DISCUSSION

The loss of visual acuity in the elderly can adversely affect their quality of life [21]. VI may cause visual difficulties in activities of daily living, leading to social isolation, depression, and anxiety [22]. Loss of vision in the elderly is associated with an increased risk of falls [23], hip fracture [24], depression [25], and poor quality of life [26].

Cataracts

Table 1. The most common causes of visual impairment in the elderly according to the some included studies

Author (year)	Region	Type of Study	Age and number of participants	First Major Cause	Second Major Cause
Thapa et al., 2018 [15]	Nepal	Cross sectional survey	Age ≥ 60 y; n = 1,860	Cataract	Retinal disorders
Gan et al., 2018 [19]	China	Cross sectional survey	Age ≥ 60 y; n = 3,789	Cataract	Refractive error
Baldev et al., 2017 [10]	Northern India	A population based cross-sectional	Age > 60 y; n = 450	Cataract	Refractive error
Cypel et al., 2017 [6]	Brazil	Cross-sectional	Age > 80 y; n = 150	Cataract	Refractive error
Pan et al., 2016 [18]	Eastern China	Community-based survey	Age > 60 y; n = 4,579	Refractive error	Cataract
Varma et al., 2016 [14]	Chinese-American	Cross-sectional	Age ≥ 50 y; 4,582	Refractive error	Cataract
Nowak et al., 2015 [13]	Poland	Cross-sectional	Age ≥ 60 y; n = 1,107	ARMD	Cataract
Zhou et al., 2012 [20]	China	Cross-sectional	Age ≥ 60 y; n = 1,305	Cataract	Fundus diseases
Chen et al., 2012 [17]	Taiwan	Cross-sectional	Age ≥ 65 y; n = 2,316	Cataract	ARMD
Tong et al., 2011 [4]	China	Cross-sectional	Age ≥ 60 y; n = 5,199	Cataract	Refractive error

Abbreviations: y, years; n, number of participants; ARMD, age-related macular degeneration.

The main causes of VI in the elderly are reported as cataracts [6, 9-18] and refractive error [6, 10, 14, 16, 18] in most of the included studies (Table 1). According to a meta-analysis of 288 studies involving 3,983,541 participants from 98 countries spanning more than three decades, among adults aged ≥ 50 years, most cases of moderate or severe VI and blindness are due to cataracts and refractive error, which are both reversible [27]. Population growth and aging have contributed to an increase in vision loss [27]. Cataracts (Figure 1) are the primary worldwide cause of visual loss in the elderly [6, 9-16]. Cataracts account for almost half of the world's 37 million cases of blindness [28]. Delaying cataract development by ten years might reduce the need for surgery by 50% [29].

Cataracts reduce performance-based visual function compared with that of unaffected individuals. Ni et al. found that uneventful cataract surgery could result in visual improvement, enhancing both performance-based and self-assessed functional vision [31]. The prevalence of cataract-related visual loss increases with age [6, 31]. Increasing age and impaired visual function are independently linked with loss of independence, including driving difficulties and placement in a nursing facility [6]. There are several modifiable risk factors for cataract development. Smoking is linked to nuclear sclerosis and posterior subcapsular cataracts [32], diabetes to cortical and posterior subcapsular cataracts [33, 34], ultraviolet light exposure to cortical and posterior subcapsular cataracts [35, 36], and myopia to all forms of cataracts. Oral corticosteroids, and to a lesser extent, inhaled corticosteroids, have been associated with posterior subcapsular cataracts [33, 34].

Cataract-associated vision loss is also related to sex and age [13, 33, 37]. Women are more likely than age-matched men to lose vision due to cataracts [13]. The risk of cataracts increases with age; by age ≥ 80 years, 70.38%, 53.48%, 60.66%, 60.86%, and 68.30% of white Americans, AAs, Hispanics, other races, and the overall population in the United States have cataracts, respectively [38].

The prevalence of blindness in men and women is 4.17% and 5.68%, respectively. Women have a 35% higher likelihood of blindness and a 69% greater chance of blindness due to cataracts [39]. Female sex accounts for 35% of the blindness prevalence and 33% of the cataract prevalence [39]. The influences of postmenopausal hormonal changes, genetics, and serum inflammatory markers in cataract development are being studied [32, 40, 41].

Considering that patients aged > 65 years with impaired vision are more likely to fall, fracture bones, and




Figure 1. Anterior segment images show surgical steps for capsulorhexis in a dense mature fluid-filled cataract (A-F). This figure has been reused with the permission of *Med Hypothesis Discov Innov Ophthalmol* [30].

require walking aids [42], elimination of the causes of VI, including cataracts, should be emphasized in the elderly. Since the first Rapid Evaluation of Avoidable Blindness (RAAB) Study in 2009 in Bhutan, a country in south-central Asia, blindness has decreased by 33%, from 1.5% in 2009 to 1.0% in 2018 [43].

The prevalence of cataracts in Chinese individuals aged 45–49 years and 85–89 years ranged from 6.71% to 73.0% in men and 8.39% to 77.51% in women, respectively [44]. The number of any cataract cases in individuals aged 45–89 years increased from 50.75 million in 1990 to 111.74 million in 2015 [44]. Between 2000 and 2010, South Central China had the most cataract cases, while Northwest China had the fewest. Because of China's aging population, cataract and cataract blindness prevalence will remain a major public health concern [44].

The Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial showed that late ARMD, bilateral cataract surgery, and visual acuity < 20/40 were all associated with a lower chance of survival [45]. In contrast, oral supplementation with omega-3 fatty acids, lutein plus zeaxanthin, zinc, or beta-carotene had no statistically significant effect on mortality [45].

Refractive Error

The major cause of VI in the United States is uncorrected refractive error [46]. In the Canadian Longitudinal Study on Aging, the most prevalent cause of vision loss was refractive error [47]. Blindness due to uncorrected refractive error rose from 6.2 million cases in 1990 to 7.4 million cases in 2015; the figures for overall VI were 84.8 million and 116.3 million cases, respectively. By 2020, the estimated number of global cases of moderate or severe VI caused by uncorrected refractive error was 127.7 million (51.0–225.3 million) [27]. It is estimated that by 2050, 866 million people will have uncorrected presbyopia [8]. Geriatric visual acuity screening is still recommended; however, the United States Preventive Services Task Force (USPSTF) found insufficient evidence to recommend screening for impaired visual acuity in adults aged ≥ 65 years. Despite convincing evidence that visual acuity tests can identify individuals with a refractive error, the USPSTF found that screening using only visual acuity testing does not accurately detect early ARMD or cataracts [48, 49]. In addition, Clarke et al. in a recent systematic review and meta-analysis found a comparable risk of poor vision in communities with and without vision screening [50]. More research is required to identify any benefits of vision screening in the elderly. Screening is intended to determine if older individuals require glasses to function normally and to avoid depression or falls that may result from impaired vision.

Although uncorrected refractive error can be as disabling as VI caused by non-correctable causes, it is easily addressed using glasses. The aging process affects several aspects of vision. The elder's vision may decrease considerably as a result of glare. Color vision and contrast sensitivity are known to decrease with age [51, 52].

Increasing time outdoors has been associated with myopia in the elderly [53]. Myopia is more prevalent in individuals aged > 70 years than in other age groups, indicating a nuclear cataract-induced myopic shift in refraction [54]. In 2010, the estimated prevalence rates of myopia in those aged ≥ 80 years among white Americans, Hispanics, other races, and AAs were 18.37%, 17.07%, 15.13%, and 10.25%, respectively [55]. Between ages 55 and 59 years, the estimated prevalence rates in white Americans, other races, Hispanics, and AAs were 22.99%, 16.76%, 14.53%, and 12.21%, respectively [55]. A meta-analysis highlighted the link between myopia and increased risks of myopic macular degeneration, retinal detachment, posterior subcapsular cataract, nuclear cataract, and open-angle glaucoma. Longer axial length, higher degree of myopia, and age ≥ 60 years were all associated with a higher risk of VI. Therefore, the priority of myopia prevention and treatment has been highlighted in the literature [56, 57].

The prevalence of hyperopia increases with age in all races. In 2010, the estimated prevalence rates of hyperopia in individuals aged ≥ 80 years among white Americans, Hispanics, AAs, and other races were 25.12%, 17.50%, 9.66%, and 1.07%, respectively, and were higher in women than in men among all age groups [58].

Glaucoma

Glaucoma increases in prevalence with age [59] (Figure 2). In 2010, 1.9% of people aged > 40 years and 7.89% of people aged > 80 years in the United States were affected by glaucoma [60]. Flaxman et al. reported that in 2015, glaucoma caused moderate or severe VI in 4 million people, and 2.9 million were blind. They predicted that glaucoma would lead to moderate or severe VI in 4.5 million people in 2020, and 3.2 million would be blind [27].

Race, sex, and age can affect the likelihood of glaucoma. Glaucoma is more common among women due to their longer lifespan [60]. AAs have the highest prevalence, and glaucoma is the leading cause of blindness in AAs [60, 61]. Undiagnosed visual disorders affect 10% of the elderly population. One of the most frequently used methods of glaucoma screening is tonometry. A dilated fundus exam is recommended by the United States Centers for Disease Control and Prevention every 1–2 years [18, 62, 63]. Goldmann applanation tonometry

remained the gold standard to which the other devices may underestimate or overestimate the intraocular pressure measurement. However, the central corneal thickness and other factors such as ethnicity could affect the accuracy of intraocular pressure measurement [64].

The prevalence of glaucoma has been reported to increase with age. Glaucoma is diagnosed in approximately 6% of AAs by the age of 69 years, and the proportion increases to 12% after the age of 80 years. Sixty-one percent of glaucoma cases in the United States are in women. It has been predicted that in 2050, 6.3 million people will have a diagnosis of glaucoma [60]. Clinical trials on pharmaceutical treatment of primary open-angle glaucoma have found that medical treatment is effective, safe, and positively affects quality of life [65, 66]. Glaucoma interventions have been summarized in a recently published review article. The novel Rho-kinase inhibitors showed significant intraocular pressure reduction [66].

Age-Related Macular Degeneration

ARMD is a progressive disease of the macula lutea that results in a gradual decline in central vision and leads to severe VI [67] (Figure 3). Among white adults over 50 years of age, the prevalence rate of ARMD was 2.5% in 2010. The prevalence rates of ARMD among people aged ≥ 80 years are 11.73% overall and 13.59% in white Americans, who have the greatest risk of ARMD compared to other races [68]. The burden of disease is predicted to increase by 2050, affecting 5.44 million people. White Americans will account for most cases, and Hispanics will experience the highest growth rate, with an almost six-fold increase in the number of expected ARMD cases from 2010 to 2050. Dietary supplements, such as vitamins and minerals, are recommended [68]. According to AREDS2, a dietary supplement formulation may lessen the likelihood of intermediate ARMD




Figure 2. Fundus photographs of the right and left eyes of a patient with glaucoma. Note the large cup-to-disc ratio, bayoneting sign, vessel barring, regional pallor, and subtle retinal nerve fiber layer defect.



Figure 3. Fundus photograph of the right eye of a patient with age-related macular degeneration. Note the hard exudate and significant macular edema caused by choroidal neovascularization.

progressing to the advanced stage [68-70].

Based on a meta-analysis, the global prevalence rate of blindness caused by macular diseases was 6.6% in 2010, accounting for 3.1% of all VI cases worldwide. The prevalence of early ARMD was estimated to be 8.0%, and late ARMD 0.4%, between the ages of 45 and 85 years. The estimated numbers of individuals with ARMD were 196 million in 2020 and 288 million in 2040. Early ARMD was found to be more common in Europeans (11.2%) than in Asians (6.8%) [71, 72]. ARMD was ranked as the fourth most common cause of blindness worldwide in 2015, accounting for an estimated 5.8% of blind people, and as the third most common cause of moderate to severe VI (3.9%) [72]. These data highlight the importance of ARMD as one of the main causes of VI in the elderly. Therefore, policymakers should consider this when planning for health enhancement of the population.

Diabetic Retinopathy




Figure 4. Severe right eye non-proliferative diabetic retinopathy and clinically significant macular edema in a 65-year-old man with corrected distance visual acuity of 40/200 in both eyes. This figure has been reused with the permission of *Med Hypothesis Discov Innov Ophthalmol* [79].




Figure 5. A 68-year-old man with active proliferative diabetic retinopathy and history of previous pan-retinal photocoagulation in his right eye. This figure has been reused with the permission of *Med Hypothesis Discov Innov Ophthalmol* [79].

According to the World Health Organization global report on diabetes published in 2016, one in every 12 adults (8.5%) has diabetes [73]. DR is the fifth leading cause of blindness and moderate to severe VI worldwide, and its prevalence is increasing in the United States. DR is a cause of vision loss in individuals aged 20–74 years [74, 75]. DR causes vision loss predominantly through diabetic macular edema and proliferative diabetic retinopathy (Figures 4 and 5) and is mostly mediated by increased retinal vascular injury and subsequent local ischemia [76–79]. From 2008 to 2010, DR accounted for 6.1% to 8.3% of VI cases in the United Kingdom. The prevalence rate of DR in 2010 for people aged ≥ 75 years was 7% in white Americans and AAs, as compared to 19% in Hispanics, who have a higher risk. In 2010, women had a higher prevalence rate than men (51% versus 49%). The prevalence rate of DR is expected to double by the year 2050, affecting 14.6 million individuals [74, 80].

This literature review included an up-to-date discussion of the most prevalent causes of VI among the elderly and of the practical applications for this pivotal subject. However, the limitations of the study are that it was performed by a single author, and only PubMed/MEDLINE was searched, which might have resulted in bias. A future review article focusing on the most common geriatric syndromes related to VI could provide practical guidelines for health policymakers to confront this globally challenging health issue.

CONCLUSIONS

VI in most ocular diseases is more prevalent in women due to their longer lifespan. Cataracts and uncorrected refractive errors are the leading causes of VI among the elderly. AAs over the age of 80 years have the highest prevalence of glaucoma, and Hispanics over the age of 80 years have the highest prevalence of DR. Depression has been linked to uncorrected refractive error in the elderly. The overall prevalence of the main causes of VI is expected to increase, which should be considered by health policymakers when planning for the health enhancement of the population.

ETHICAL DECLARATIONS

Ethical Approval: This study was a review, and no ethical approval was required.

Conflict of Interest: None

FUNDING

None

ACKNOWLEDGEMENTS

None

REFERENCES

- Orimo H. [Reviewing the definition of elderly]. *Nihon Ronen Igakkai Zasshi*. 2006;43(1):27-34. Japanese. doi: 10.3143/geriatrics.43.27 pmid: 16521795
- Owsley C. Aging and vision. *Vision Res*. 2011;51(13):1610-22. doi: 10.1016/j.visres.2010.10.020 pmid: 20974168
- Bourne RRA, Flaxman SR, Braithwaite T, Cicinelli MV, Das A, Jonas JB, et al; Vision Loss Expert Group. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. *Lancet Glob Health*. 2017;5(9):e888-e897. doi: 10.1016/S2214-109X(17)30293-0 pmid: 28779882
- Tong XW, Zhao R, Zou HD, Zhu JF, Wang J, Yu J, et al. [A prevalence investigation of blindness and vision impairment in 2009 in older adults of Dachang Blocks of Baoshan District, Shanghai, China]. *Zhonghua Yan Ke Za Zhi*. 2011;47(9):785-90. Chinese. pmid: 22177122
- Larsen PP, Thiele S, Krohne TU, Ziemssen F, Krummenauer F, Holz FG, et al; OVIS-Study Group. Visual impairment and blindness in institutionalized elderly in Germany. *Graefes Arch Clin Exp Ophthalmol*. 2019;257(2):363-370. doi: 10.1007/s00417-018-4196-1 Erratum in: *Graefes Arch Clin Exp Ophthalmol*. 2019. pmid: 30483949
- Cypel MC, Salomão SR, Dantas PEC, Lottenberg CL, Kasahara N, Ramos LR, et al. Vision status, ophthalmic assessment, and quality of life in the very old. *Arq Bras Oftalmol*. 2017;80(3):159-164. doi: 10.5935/0004-2749.20170039 pmid: 28832732
- National Institutes of Health. National Eye Institute (2020). 'All vision impairment'. Available at :<https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/all-vision-impairment-data-and-statistics> (Accessed: April 29, 2021)
- GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. *Lancet Glob Health*. 2021;9(2):e130-e143. doi: 10.1016/S2214-109X(20)30425-3 pmid: 33275950
- Gan S, Zhou X, Yan J, Liu X, Yi J, Zhou X, et al. The prevalence and risk factors of visual impairment among rural residents aged 50 years and above in Yugan county, China. *Ophthalmic Epidemiol*. 2018;25(5-6):331-337. doi: 10.1080/09286586.2018.1476557 pmid:

- 29842804
10. Baldev VF, Chopra R, Batra N, Singh S. Pattern of Ocular Morbidity in the Elderly Population of Northern India. *J Clin Diagn Res.* 2017;11(8):NC20-NC23. doi: [10.7860/JCDR/2017/27056.10496](https://doi.org/10.7860/JCDR/2017/27056.10496) pmid: 28969173
 11. Tsai SY, Hsu WM, Cheng CY, Liu JH, Chou P. Epidemiologic study of age-related cataracts among an elderly Chinese population in Shih-Pai, Taiwan. *Ophthalmology.* 2003;110(6):1089-95. doi: [10.1016/S0161-6420\(03\)00243-4](https://doi.org/10.1016/S0161-6420(03)00243-4) pmid: 12799231
 12. Tang Y, Wang X, Wang J, Huang W, Gao Y, Luo Y, et al. Prevalence and Causes of Visual Impairment in a Chinese Adult Population: The Taizhou Eye Study. *Ophthalmology.* 2015;122(7):1480-8. doi: [10.1016/j.ophtha.2015.03.022](https://doi.org/10.1016/j.ophtha.2015.03.022) pmid: 25986897
 13. Nowak MS, Smigielski J. The prevalence and causes of visual impairment and blindness among older adults in the city of Lodz, Poland. *Medicine (Baltimore).* 2015;94(5):e505. doi: [10.1097/MD.0000000000000505](https://doi.org/10.1097/MD.0000000000000505). Erratum in: *Medicine (Baltimore).* 2015;94(7):1. pmid: 25654398
 14. Varma R, Kim JS, Burkemper BS, Wen G, Torres M, Hsu C, et al; Chinese American Eye Study Group. Prevalence and Causes of Visual Impairment and Blindness in Chinese American Adults: The Chinese American Eye Study. *JAMA Ophthalmol.* 2016;134(7):785-93. doi: [10.1001/jamaophthalmol.2016.1261](https://doi.org/10.1001/jamaophthalmol.2016.1261) pmid: 27196952
 15. Thapa R, Bajimaya S, Paudyal G, Khanal S, Tan S, Thapa SS, et al. Prevalence and causes of low vision and blindness in an elderly population in Nepal: the Bhaktapur retina study. *BMC Ophthalmol.* 2018;18(1):42. doi: [10.1186/s12886-018-0710-9](https://doi.org/10.1186/s12886-018-0710-9) pmid: 29439666
 16. Shen H, Zhang H, Gong W, Qian T, Cheng T, Jin L, et al. Prevalence, Causes, and Factors Associated with Visual Impairment in a Chinese Elderly Population: The Rugao Longevity and Aging Study. *Clin Interv Aging.* 2021;16:985-996. doi: [10.2147/CIA.S304730](https://doi.org/10.2147/CIA.S304730) pmid: 34079244
 17. Chen N, Huang TL, Tsai RK, Sheu MM. Prevalence and causes of visual impairment in elderly Amis aborigines in Eastern Taiwan (the Amis Eye Study). *Jpn J Ophthalmol.* 2012;56(6):624-30. doi: [10.1007/s10384-012-0178-8](https://doi.org/10.1007/s10384-012-0178-8) pmid: 22961342
 18. Pan CW, Qian DJ, Sun HP, Ma Q, Xu Y, Song E. Visual Impairment among Older Adults in a Rural Community in Eastern China. *J Ophthalmol.* 2016;2016:9620542. doi: [10.1155/2016/9620542](https://doi.org/10.1155/2016/9620542) pmid: 27777793
 19. Gan SH, Deng LL, Zhou XJ, Yi JL, Zhou QQ, Li YP, et al. [Prevalence status and influencing factors of visual impairment in the elderly people in rural areas of Yugan County, Jiangxi Province]. *Zhonghua Yan Ke Za Zhi.* 2018;54(8):605-610. Chinese. doi: [10.3760/cma.j.issn.0412-4081.2018.08.008](https://doi.org/10.3760/cma.j.issn.0412-4081.2018.08.008) pmid: 30107654
 20. Zhou J, Yuan Y, Zhang X, Guan HJ. [A prevalence investigation of blindness and low vision in 2008 among adults aged 60 years or above in 2 villages of Nantong]. *Zhonghua Yan Ke Za Zhi.* 2012;48(10):908-14. Chinese. pmid: 23302246
 21. Lamoureux E, Pesudovs K. Vision-specific quality-of-life research: a need to improve the quality. *Am J Ophthalmol.* 2011;151(2):195-7.e2. doi: [10.1016/j.ajo.2010.09.020](https://doi.org/10.1016/j.ajo.2010.09.020) pmid: 21251493
 22. Tetteh J, Fordjour G, Ekem-Ferguson G, Yawson AO, Boima V, Entsuaeh-Mensah K, et al. Visual impairment and social isolation, depression and life satisfaction among older adults in Ghana: analysis of the WHO's Study on global AGEing and adult health (SAGE) Wave 2. *BMJ Open Ophthalmol.* 2020;5(1):e000492. doi: [10.1136/bmjophth-2020-000492](https://doi.org/10.1136/bmjophth-2020-000492) pmid: 32626826
 23. Crews JE, DPA, Chou CF, Stevens JA, Saadine JB. Falls Among Persons Aged ≥65 Years With and Without Severe Vision Impairment - United States, 2014. *MMWR Morb Mortal Wkly Rep.* 2016;65(17):433-7. doi: [10.15585/mmwr.mm6517a2](https://doi.org/10.15585/mmwr.mm6517a2) pmid: 27148832
 24. Tseng VL, Yu F, Lum F, Coleman AL. Risk of fractures following cataract surgery in Medicare beneficiaries. *JAMA.* 2012;308(5):493-501. doi: [10.1001/jama.2012.9014](https://doi.org/10.1001/jama.2012.9014) pmid: 22851116
 25. Rovner BW, Casten RJ, Hegel MT, Massof RW, Leiby BE, Ho AC, et al. Low vision depression prevention trial in age-related macular degeneration: a randomized clinical trial. *Ophthalmology.* 2014;121(11):2204-11. doi: [10.1016/j.ophtha.2014.05.002](https://doi.org/10.1016/j.ophtha.2014.05.002) pmid: 25016366
 26. Jones SA, Shinton RA. Improving outcome in stroke patients with visual problems. *Age Ageing.* 2006;35(6):560-5. doi: [10.1093/ageing/af074](https://doi.org/10.1093/ageing/af074) pmid: 16820528
 27. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al; Vision Loss Expert Group of the Global Burden of Disease Study. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. *Lancet Glob Health.* 2017;5(12):e1221-e1234. doi: [10.1016/S2214-109X\(17\)30393-5](https://doi.org/10.1016/S2214-109X(17)30393-5) pmid: 29032195
 28. Tabin G, Chen M, Espandar L. Cataract surgery for the developing world. *Curr Opin Ophthalmol.* 2008;19(1):55-9. doi: [10.1097/ICU.0b013e3282f154bd](https://doi.org/10.1097/ICU.0b013e3282f154bd) pmid: 18090899
 29. Congdon NG. Prevention strategies for age related cataract: present limitations and future possibilities. *Br J Ophthalmol.* 2001;85(5):516-20. doi: [10.1136/bjo.85.5.516](https://doi.org/10.1136/bjo.85.5.516) pmid: 11316704
 30. Ghoneim EM. Modified capsulorhexis for fluid-filled mature cataracts. *Med Hypothesis Discov Innov Ophthalmol.* 2021 Summer; 10(2): 59-66. doi: [10.51329/mehdiptometry1422](https://doi.org/10.51329/mehdiptometry1422)
 31. Ni W, Li X, Hou Z, Zhang H, Qiu W, Wang W. Impact of cataract surgery on vision-related life performances: the usefulness of Real-Life Vision Test for cataract surgery outcomes evaluation. *Eye (Lond).* 2015;29(12):1545-54. doi: [10.1038/eye.2015.147](https://doi.org/10.1038/eye.2015.147) pmid: 26272444
 32. West SK. Looking forward to 20/20: a focus on the epidemiology of eye diseases. *Epidemiol Rev.* 2000;22(1):64-70. doi: [10.1093/oxfordjournals.epirev.a018025](https://doi.org/10.1093/oxfordjournals.epirev.a018025) pmid: 10939008
 33. Delcourt C, Cristol JP, Tessier F, Léger CL, Michel F, Papoz L. Risk factors for cortical, nuclear, and posterior subcapsular cataracts: the POLA study. *Pathologies Oculaires Liées à l'Age.* *Am J Epidemiol.* 2000;151(5):497-504. doi: [10.1093/oxfordjournals.aje.a010235](https://doi.org/10.1093/oxfordjournals.aje.a010235) pmid: 10707918
 34. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. *Curr Opin Ophthalmol.* 2000;11(6):478-83. doi: [10.1097/00055735-200012000-00016](https://doi.org/10.1097/00055735-200012000-00016) pmid: 11141645
 35. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related nuclear and cortical cataract: a case-control study in the Age-Related Eye Disease Study, AREDS Report No. 5. *Ophthalmology.* 2001;108(8):1400-8. doi: [10.1016/s0161-6420\(01\)00626-1](https://doi.org/10.1016/s0161-6420(01)00626-1) pmid: 11470690
 36. Katoh N, Jonasson F, Sasaki H, Kojima M, Ono M, Takahashi N, et al; Reykjavik Eye Study Group. Cortical lens opacification in Iceland. Risk factor analysis -- Reykjavik Eye Study. *Acta Ophthalmol Scand.* 2001;79(2):154-9. doi: [10.1034/j.1600-0420.2001.079002154.x](https://doi.org/10.1034/j.1600-0420.2001.079002154.x) pmid: 11284753
 37. Vashist P, Talwar B, Gogoi M, Maraini G, Camparini M, Ravindran RD, et al. Prevalence of cataract in an older population in India: the India study of age-related eye disease. *Ophthalmology.* 2011;118(2):272-8.e1-2. doi: [10.1016/j.ophtha.2010.05.020](https://doi.org/10.1016/j.ophtha.2010.05.020) pmid: 20801514

38. National Institutes of Health. National Eye Institute (2019). 'Cataract Data and Statistics'. Available at :<https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/cataract-data-and-statistics> (Accessed: April 29, 2021)
39. Prasad M, Malhotra S, Kalaivani M, Vashist P, Gupta SK. Gender differences in blindness, cataract blindness and cataract surgical coverage in India: a systematic review and meta-analysis. *Br J Ophthalmol.* 2020;104(2):220-224. doi: 10.1136/bjophthalmol-2018-313562 pmid: 31221669
40. Lai K, Cui J, Ni S, Zhang Y, He J, Yao K. The effects of postmenopausal hormone use on cataract: a meta-analysis. *PLoS One.* 2013;8(10):e78647. doi: 10.1371/journal.pone.0078647 pmid: 24205286
41. Klein BE, Klein R, Lee KE, Knudtson MD, Tsai MY. Markers of inflammation, vascular endothelial dysfunction, and age-related cataract. *Am J Ophthalmol.* 2006;141(1):116-22. doi: 10.1016/j.ajo.2005.08.021 pmid: 16386984
42. Brundel C, Waterman HA, Ballinger C, Ollevent N, Skelton DA, Stanford P, et al. The causes of falls: views of older people with visual impairment. *Health Expect.* 2015;18(6):2021-31. doi: 10.1111/hex.12355 pmid: 25736829
43. Lepcha NT, Sharma IP, Sapkota YD, Das T, Phuntsho T, Tenzin N, et al. Changing trends of blindness, visual impairment and cataract surgery in Bhutan: 2009-2018. *PLoS One.* 2019;14(5):e0216398. doi: 10.1371/journal.pone.0216398 pmid: 31071127
44. Song P, Wang H, Theodoratou E, Chan KY, Rudan I. The national and subnational prevalence of cataract and cataract blindness in China: a systematic review and meta-analysis. *J Glob Health.* 2018;8(1):010804. doi: 10.7189/jogh.08-010804 pmid: 29977532
45. Age-Related Eye Disease Study 2 Research Group, Papudesu C, Clemons TE, Agrón E, Chew EY. Association of Mortality with Ocular Diseases and Visual Impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. *Ophthalmology.* 2018;125(4):512-521. doi: 10.1016/j.ophtha.2017.10.028 pmid: 29153456
46. Chou CF, Frances Cotch M, Vitale S, Zhang X, Klein R, Friedman DS, et al. Age-related eye diseases and visual impairment among U.S. adults. *Am J Prev Med.* 2013;45(1):29-35. doi: 10.1016/j.amepre.2013.02.018 pmid: 23790986
47. Aljied R, Aubin MJ, Buhmann R, Sabeti S, Freeman EE. Prevalence and determinants of visual impairment in Canada: cross-sectional data from the Canadian Longitudinal Study on Aging. *Can J Ophthalmol.* 2018;53(3):291-297. doi: 10.1016/j.cjco.2018.01.027 pmid: 29784168
48. Screening for Impaired Visual Acuity in Older Adults: Recommendation Statement. *Am Fam Physician.* 2016;93(12):Online. pmid: 27304779
49. Chou R, Dana T, Bougatsos C, Grusing S, Blazina I. Screening for Impaired Visual Acuity in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA.* 2016;315(9):915-33. doi: 10.1001/jama.2016.0783 pmid: 26934261
50. Clarke EL, Evans JR, Smeeth L. Community screening for visual impairment in older people. *Cochrane Database Syst Rev.* 2018;2(2):CD001054. doi: 10.1002/14651858.CD001054.pub3 pmid: 29460275
51. Ferraz FH, Corrente JE, Opromolla P, Schellini SA. Influence of uncorrected refractive error and unmet refractive error on visual impairment in a Brazilian population. *BMC Ophthalmol.* 2014;14:84. doi: 10.1186/1471-2415-14-84 pmid: 24965318
52. Salvi SM, Akhtar S, Currie Z. Ageing changes in the eye. *Postgrad Med J.* 2006;82(971):581-7. doi: 10.1136/pgmj.2005.040857 pmid: 16954455
53. Joseph S, Krishnan T, Ravindran RD, Maraini G, Camparini M, Chakravarthy U, et al. Prevalence and risk factors for myopia and other refractive errors in an adult population in southern India. *Ophthalmic Physiol Opt.* 2018;38(3):346-358. doi: 10.1111/opo.12447 pmid: 29574882
54. Pan CW, Dirani M, Cheng CY, Wong TY, Saw SM. The age-specific prevalence of myopia in Asia: a meta-analysis. *Optom Vis Sci.* 2015;92(3):258-66. doi: 10.1097/OPX.0000000000000516 pmid: 25611765
55. National Institutes of Health. National Eye Institute (2019). 'Nearsightedness (Myopia) Data and Statistics'. Available at: <https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/nearsightedness-myopia-data-and-statistics> (Accessed: April 29, 2021)
56. Haarman AEG, Enthoven CA, Tideman JW, Tedja MS, Verhoeven VJM, Klaver CCW. The Complications of Myopia: A Review and Meta-Analysis. *Invest Ophthalmol Vis Sci.* 2020;61(4):49. doi: 10.1167/iov.61.4.49 pmid: 32347918
57. Tideman JW, Snabel MC, Tedja MS, van Rijn GA, Wong KT, Kuijpers RW, et al. Association of Axial Length With Risk of Uncorrectable Visual Impairment for Europeans With Myopia. *JAMA Ophthalmol.* 2016;134(12):1355-1363. doi: 10.1001/jamaophthalmol.2016.4009 pmid: 27768171
58. National Institutes of Health. National Eye Institute (2019). 'Farsightedness (Hyperopia) Data and Statistics'. Available at: <https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/farsightedness-hyperopia-data-and-statistics> (Accessed: April 29, 2021)
59. European Glaucoma Prevention Study (EGPS) Group, Miglior S, Pfeiffer N, Torri V, Zeyen T, Cunha-Vaz J, Adamsons I. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. *Ophthalmology.* 2007;114(1):3-9. doi: 10.1016/j.ophtha.2006.05.075 pmid: 17070596
60. National Institutes of Health. National Eye Institute (2019). 'Glaucoma Data and Statistics'. Available at: <https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/glaucoma-data-and-statistics> (Accessed: April 29, 2021)
61. Restrepo NA, Laper SM, Farber-Eger E, Crawford DC. Local genetic ancestry in CDKN2B-AS1 is associated with primary open-angle glaucoma in an African American cohort extracted from de-identified electronic health records. *BMC Med Genomics.* 2018;11(Suppl 3):70. doi: 10.1186/s12920-018-0392-4 pmid: 30255811
62. Aziz K, Friedman DS. Tonometers-which one should I use? *Eye (Lond).* 2018;32(5):931-937. doi: 10.1038/s41433-018-0040-4 pmid: 29456251
63. Centers for Disease Control and Prevention. Vision Health Initiative (2020). 'Keep an Eye on Your Vision Health'. Available at: <https://www.cdc.gov/visionhealth/resources/features/keep-eye-on-vision-health.html> (Accessed: April 29, 2021)
64. Salouti R, Alishiri AA, Gharebaghi R, Naderi M, Jadidi K, Shojaei-Baghini A, et al. Comparison among Ocular Response Analyzer, Corvis ST and Goldmann applanation tonometry in healthy children. *Int J Ophthalmol.* 2018;11(8):1330-1336. doi: 10.18240/

- ijo.2018.08.13 pmid: 30140637
65. Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW, Guire KE, et al; CIGTS Study Group. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. *Ophthalmology*. 2001;108(11):1954-65. doi: 10.1016/s0161-6420(01)00874-0 pmid: 11713062
 66. Al-Namaeh M. Pharmaceutical treatment of primary open angle glaucoma. *Medical hypothesis, discovery & innovation in optometry*. 2021;2(1):8-17. doi: 10.51329/mehdiopometry120
 67. Ramin S, Soheilian M, Habibi G, Ghazavi R, Gharebaghi R, Heidary F. Age-Related Macular Degeneration: A Scientometric Analysis. *Med Hypothesis Discov Innov Ophthalmol*. 2015;4(2):39-49. pmid: 26060829
 68. National Institutes of Health. National Eye Institute (2019). 'Age-Related Macular Degeneration (AMD) Data and Statistics'. Available at: <https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/age-related-macular-degeneration-amd-data-and-statistics> (Accessed April 29, 2021)
 69. AREDS2 Research Group, Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally A, McBee W, et al. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). *Ophthalmology*. 2012;119(11):2282-9. doi: 10.1016/j.ophtha.2012.05.027 pmid: 22840421
 70. Sin HP, Liu DT, Lam DS. Lifestyle modification, nutritional and vitamins supplements for age-related macular degeneration. *Acta Ophthalmol*. 2013;91(1):6-11. doi: 10.1111/j.1755-3768.2011.02357.x pmid: 22268800
 71. Jonas JB, Bourne RR, White RA, Flaxman SR, Keeffe J, Leasher J, et al; Vision Loss Expert Group of the Global Burden of Disease Study. Visual impairment and blindness due to macular diseases globally: a systematic review and meta-analysis. *Am J Ophthalmol*. 2014;158(4):808-15. doi: 10.1016/j.ajo.2014.06.012 pmid: 24973605
 72. Jonas JB, Cheung CMG, Panda-Jonas S. Updates on the Epidemiology of Age-Related Macular Degeneration. *Asia Pac J Ophthalmol (Phila)*. 2017;6(6):493-497. doi: 10.22608/APO.2017251 pmid: 28906084
 73. world health organization (2016). 'Global report on diabetes'. Available at: <https://www.who.int/publications/i/item/9789241565257> (Accessed April 29, 2021)
 74. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. *Eye Vis (Lond)*. 2015;2:17. doi: 10.1186/s40662-015-0026-2 pmid: 26605370
 75. Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. *JAMA*. 2010;304(6):649-56. doi: 10.1001/jama.2010.1111 pmid: 20699456
 76. Wykoff CC. Management of Diabetes-Related Retinopathy. In: *Prevention and Management of Diabetes-Related Eye Disease*. American Diabetes Association; 2019 May. Bookshelf ID: NBK544520. doi: 10.2337/db20191-11 pmid: 34251786
 77. Zhang C, Wang H, Nie J, Wang F. Protective factors in diabetic retinopathy: focus on blood-retinal barrier. *Discov Med*. 2014 Sep;18(98):105-12. pmid: 25227751
 78. Roy S, Kern TS, Song B, Stuebe C. Mechanistic Insights into Pathological Changes in the Diabetic Retina: Implications for Targeting Diabetic Retinopathy. *Am J Pathol*. 2017;187(1):9-19. doi: 10.1016/j.ajpath.2016.08.022 pmid: 27846381
 79. Afarid M, Attarzadeh A, Farvardin M, Ashraf H. The Association of Serum Leptin Level and Anthropometric Measures With the Severity of Diabetic Retinopathy in Type 2 Diabetes Mellitus. *Med Hypothesis Discov Innov Ophthalmol*. 2018;7(4):156-162. pmid: 30505866
 80. National Institutes of Health. National Eye Institute (2020). 'Diabetic Retinopathy Data and Statistics'. Available at: <https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/diabetic-retinopathy-data-and-statistics> (Accessed: April 29, 2021)